(Q24242402)

https://api.crossref.org/works/10.1002%2F14651858.CD001765.PUB3

Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001765.PUB3

Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001765.PUB3

An Inventory for Measuring Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001765.PUB3

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001765.PUB3

Meta-analysis: principles and procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001765.PUB3

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001765.PUB3

Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001765.PUB3

The assessment of anxiety states by rating

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001765.PUB3

Development of a Rating Scale for Primary Depressive Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001765.PUB3

A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001765.PUB3

The epidemiology of obsessive-compulsive disorder in five US communities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001765.PUB3

Why sources of heterogeneity in meta-analysis should be investigated

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001765.PUB3

Hoarding and Treatment Response in 38 Nondepressed Subjects With Obsessive-Compulsive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001765.PUB3

Cognitive behaviour therapy and medication in the treatment of obsessive-compulsive disorder

21 January 2018

1 reference

12 December 2020

Episodic and chronic obsessive-compulsive disorder.

1 reference

12 December 2020

Obsessional-compulsive complaints

1 reference

12 December 2020

Serum cholesterol in patients with obsessive compulsive disorder during treatment with behavior therapy and SSRI or placebo

1 reference

12 December 2020

Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder

1 reference

12 December 2020

A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder.

1 reference

12 December 2020

Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder

1 reference

12 December 2020

Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis.

1 reference

12 December 2020

Side effects as predictors of drug response in obsessive-compulsive disorder

1 reference

12 December 2020

Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy.

1 reference

12 December 2020

Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder.

1 reference

12 December 2020

Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study

1 reference

12 December 2020

Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: a meta-analysis

1 reference

12 December 2020

Full publication of results initially presented in abstracts. A meta-analysis

1 reference

12 December 2020

Fluoxetine: no association with suicidality in obsessive-compulsive disorder

1 reference

12 December 2020

Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators

1 reference

12 December 2020

Dystonic reaction associated with fluvoxamine

1 reference

12 December 2020

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

1 reference

12 December 2020

Fluvoxamine-associated mania/hypomania in patients with obsessive-compulsive disorder

1 reference

12 December 2020

Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder

1 reference

12 December 2020

Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder

1 reference

12 December 2020

Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.

1 reference

12 December 2020

Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo.

1 reference

12 December 2020

Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder.

1 reference

12 December 2020

Obsessive compulsive disorder

1 reference

12 December 2020

Neurological soft signs as predictors of treatment response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder

1 reference

12 December 2020

Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards

1 reference

12 December 2020

Clinical predictors of drug response in obsessive-compulsive disorder.

1 reference

12 December 2020

Fluvoxamine treatment of obsessive-compulsive disorder

1 reference

12 December 2020

The pattern of burden in families of neurotic patients.

1 reference

12 December 2020

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

1 reference

12 December 2020

An inventory for measuring clinical anxiety: psychometric properties

1 reference

12 December 2020

Standardised assessment and recording of depressive symptoms

1 reference

12 December 2020

Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder

1 reference

12 December 2020

Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study

1 reference

12 December 2020

A randomized controlled trial of Japanese patients with obsessive-compulsive disorder--effectiveness of behavior therapy and fluvoxamine

1 reference

12 December 2020

Serotonergic antidepressants and their efficacy in obsessive compulsive disorder

1 reference

12 December 2020

Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder

1 reference

12 December 2020

Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder.

1 reference

12 December 2020

Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients

1 reference

12 December 2020

Compulsive exhibitionism successfully treated with fluvoxamine: a controlled case study

1 reference

12 December 2020

A 2-year study of sertraline in the treatment of obsessive-compulsive disorder.

1 reference

12 December 2020

Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year followup

1 reference

12 December 2020

Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder

1 reference

12 December 2020

A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.

1 reference

12 December 2020

Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.

1 reference

12 December 2020

A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder

1 reference

12 December 2020

Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients

1 reference

12 December 2020

Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder

1 reference

12 December 2020

Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study.

1 reference

12 December 2020

Fluoxetine treatment of obsessive-compulsive disorder

1 reference

12 December 2020

A 40-year follow-up of patients with obsessive-compulsive disorder [see commetns]

1 reference

12 December 2020

Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder

1 reference

12 December 2020

Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses.

1 reference

12 December 2020

The serotonin hypothesis of obsessive compulsive disorder

1 reference

12 December 2020

Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine

1 reference

12 December 2020

Sertraline in the treatment of obsessive-compulsive disorder

1 reference

12 December 2020

Publication bias in clinical research

1 reference

12 December 2020

Behavior therapy and tricyclic medication in the treatment of obsessive-compulsive disorder: a quantitative review

1 reference

12 December 2020

Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study

1 reference

12 December 2020

Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo

1 reference

12 December 2020

Is there a serotonergic withdrawal syndrome?

1 reference

12 December 2020

A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder

1 reference

12 December 2020

Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review

1 reference

12 December 2020

Treatment outlines for the management of obsessive-compulsive disorders. The Quality Assurance Project

1 reference

12 December 2020

Epidemiology of obsessive-compulsive disorder.

1 reference

12 December 2020

Different roles for serotonin in anti-obsessional drug action and the pathophysiology of obsessive-compulsive disorder.

1 reference

12 December 2020

Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review

2 references

12 December 2020

https://api.crossref.org/works/10.1002%2F14651858.CD001765.PUB3

7 January 2021

inferred from DOI database lookup

Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder

1 reference

12 December 2020

A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group

1 reference

12 December 2020

The Yale-Brown Obsessive-Compulsive Scale: a reliability and validity study

1 reference

12 December 2020

Effect Measures for Meta-Analysis of Trials with Binary Outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001765.PUB3

7 January 2021

inferred from DOI database lookup

Assessing the Quality of Randomised Controlled Trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001765.PUB3

7 January 2021